泌尿器科領域におけるT-3262の臨床的検討

DOI

書誌事項

タイトル別名
  • T-3262 IN UROLOGY

説明

We clinically investigated T-3262, a new antimicrobial agent derived from pyridone-carboxylic acid.<BR>Twenty-five patients with urinary tract infection were treated with T-3262, and the clinical efficacy in 24 patients was evaluated by the criteria of the Japanese UTI Committee. The clinical response in 15 cases of acute uncomplicated cystitis was excellent in 10 cases and moderate in 5 and in both cases of acute uncomplicated pyelonephritis it was excellent. The overall clinical efficacy rate for acute uncomplicated UTI was 100%. The clinical response in 7 patients with chronic complicated cystitis was excellent in 4, the overall efficacy rate being 57.1%. The efficacy was fair in 1 case of chronic complicated pyelonephritis according to the evaluation of the doctor in charge.<BR>Bacteriological response was evaluated in the above 24 cases. Eradication of bacteria was observed in all 17 strains isolated (100%) in uncomplicated UTI and in 6 of 10 strains (60%) in complicated UTI. No adverse reactions were seen.<BR>Our results suggest that T-3262 is useful in treating urinary tract infections.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ